Delgocitinib ointment, as a local JAK inhibitor, is mainly used for the treatment of atopic dermatitis. Its indications are clear and specific medication risks should be noted. The following is a detailed explanation of indications and key precautions.

1 Indications

(1) Atopic dermatitis: suitable for local treatment of moderate to severe atopic dermatitis in adults and children over 2 years old.

(2) Chronic eczema: It may be considered for patients with chronic hand eczema who have not responded to traditional treatments.

(3) Skin lesion range: Recommended for localized skin lesions with a body surface area of ≤ 15%, avoiding long-term use over a large area.

2 Medication precautions

(1) Skin reaction: The medication site may experience burning, itching, or redness, and if it persists for more than 72 hours, the medication needs to be stopped for evaluation.

(2) Infection monitoring: If skin suppuration or herpes like lesions occur during treatment, medication should be stopped immediately and anti infection treatment should be administered.

(3) Contact protection: Avoid contact of ointment with eyes and mucous membranes, wash hands thoroughly after administration to prevent accidental contact and transmission.

Attention to 3 special groups

(1) Children: Prohibited for children under 2 years old, dosage should be adjusted according to 0.5mg/cm ² body surface area for children aged 2-11.

(2) Pregnancy: Animal experiments have shown embryotoxicity, human data is limited, and it is contraindicated during pregnancy.

(3) Liver dysfunction: Moderate damage patients need to reduce dosage by 50%, and Child Pugh Class C patients are absolutely prohibited.

4 Course Management

(1) Usage time limit: Continuous medication should not exceed 4 weeks, and a new course of treatment can be started with an interval of at least 2 weeks.

(2) Efficacy evaluation: If there is no improvement after 2 weeks of medication, a new diagnosis should be made. If there is no improvement after 4 weeks, the treatment plan should be changed.

(3) Long term risk: may cause skin atrophy or capillary dilation, requiring regular dermatological follow-up.